Brainomix vs RapidAI

A health system that wants pulmonary embolism and aortic modules under its stroke contract finds them on RapidAI's homepage, which lists aneurysm, aortic and pulmonary embolism modules next to stroke. Brainomix's solutions pages list stroke, CT lung quantification and network analytics (Vantage), so Brainomix loses that buyer to RapidAI. RapidAI's openFDA trail starts with iSchemaView RAPID in October 2013 (K121447), runs through Rapid LVO in July 2020 (K200941) and reaches Rapid 6.0 in January 2024 (K233512). The vendor claims 30 FDA-cleared modules and 2,500 hospitals, both marketing figures, and Crunchbase and Tracxn profiles put its funding near $100 million.

Brainomix's first openFDA record is e-CTA in May 2020, and the vendor claims 35 or more clearances worldwide. It suits a stroke service that wants MRI-based selection: e-MRI covers DWI-FLAIR mismatch (K231656), and its triage decisions cover LVO (K231837), ICH (K231195) and stroke (K232496).